Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function [PDF]
Platelets, 2022 Several Janus kinase (JAK) inhibitors (jakinibs) have recently been approved to treat inflammatory, autoimmune and hematological conditions. Despite emerging roles for JAKs and downstream signal transducer and activator of transcription (STAT) proteins ...
Iván Parra-Izquierdo +9 more
doaj +2 more sources
Platelet glycoprotein VI promotes folic acid-induced acute kidney injury through interaction with tubular epithelial cell-derived galectin-3 [PDF]
Cell Communication and SignalingBackground Acute kidney injury (AKI) is defined by a significant reduction in renal function, which subsequently impairs coagulation and activates the inflammatory immune response, ultimately resulting in damage to renal tubular epithelial cells (TECs ...
Ya-Wei Guo +8 more
doaj +2 more sources
Glenzocimab does not impact glycoprotein VI-dependent inflammatory hemostasis
Haematologica, 2020 Not available.
Soumaya Jadoui +14 more
doaj +6 more sources
Long-term platelet priming after glycoprotein VI stimulation in comparison to Protease-Activating Receptor (PAR) stimulation. [PDF]
PLoS ONE, 2021 Platelets can respond to multiple antagonists and agonists, implying that their activation state is a consequence of past exposure to these substances.
Jinmi Zou +3 more
doaj +2 more sources
Glycoprotein VI Blockade: Not Just Targeting Collagen Anymore? [PDF]
Arterioscler Thromb Vasc Biol, 2020 Gupta S, Brass LF.
europepmc +4 more sources
Glycoprotein VI in securing vascular integrity in inflamed vessels. [PDF]
Res Pract Thromb Haemost, 2018 Glycoprotein VI (GPVI), the main platelet receptor for collagen, has been shown to play a central role in various models of thrombosis, and to be a minor actor of hemostasis at sites of trauma. These observations have made of GPVI a novel target for antithrombotic therapy, as its inhibition would ideally combine efficacy with safety.
Boulaftali Y +3 more
europepmc +4 more sources
Quantitative Characterization of Shear-Induced Platelet Receptor Shedding: Glycoprotein Ibα, Glycoprotein VI, and Glycoprotein IIb/IIIa. [PDF]
ASAIO J, 2018 The structural integrity of platelet receptors is essential for platelets to play the normal hemostatic function. The high non-physiologic shear stress (NPSS) commonly exists in blood-contacting medical devices and has been shown to cause platelet receptor shedding.
Chen Z +4 more
europepmc +4 more sources
Is glycoprotein VI involved in contractual negotiations? [PDF]
Res Pract Thromb HaemostBrysland SA, Hearn JI, Gardiner EE.
europepmc +3 more sources
The future of glycoprotein VI as an antithrombotic target [PDF]
Journal of Thrombosis and Haemostasis, 2012 The treatment of acute coronary syndromes has been considerably improved in recent years with the introduction of highly efficient antiplatelet drugs. However, there are still significant limitations: the recurrence of adverse vascular events remains a problem, and the improvement in efficacy is counterbalanced by an increased risk of bleeding, which ...
M, Zahid +6 more
openaire +2 more sources
Platelets, 2021 Most agonists stimulate platelet Ca2+ rises via G-protein coupled receptors (GPCRs) or ITAM-linked receptors (ILRs). Well studied are the GPCRs stimulated by the soluble agonists thrombin (PAR1, PAR4), ADP (P2Y1, P2Y12), and thromboxane A2 (TP ...
Delia I. Fernández +2 more
doaj +1 more source